The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...
AKTX-102 is a first-in-class ADC that combines a novel CEACAM5-targeting antibody construct with Akari’s proprietary PH1 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果